Compare LXU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | ANAB |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | United States | United States |
| Employees | 513 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2006 | 2015 |
| Metric | LXU | ANAB |
|---|---|---|
| Price | $13.82 | $70.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $14.63 | ★ $74.64 |
| AVG Volume (30 Days) | ★ 1.9M | 553.9K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | 91.02 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $615,208,000.00 | $234,603,000.00 |
| Revenue This Year | $10.78 | N/A |
| Revenue Next Year | N/A | $31.11 |
| P/E Ratio | $41.94 | ★ N/A |
| Revenue Growth | 17.77 | ★ 157.01 |
| 52 Week Low | $4.92 | $17.11 |
| 52 Week High | $17.22 | $73.30 |
| Indicator | LXU | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 65.81 |
| Support Level | $7.88 | $53.46 |
| Resistance Level | $15.66 | N/A |
| Average True Range (ATR) | 0.99 | 4.40 |
| MACD | -0.33 | 0.83 |
| Stochastic Oscillator | 17.29 | 84.92 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).